JP2004520264A - 鉄錯化蛋白質および一酸化窒素代謝の前駆体および／または一酸化窒素の化学的ドナーを含有する組成物ならびにその使用 - Google Patents
鉄錯化蛋白質および一酸化窒素代謝の前駆体および／または一酸化窒素の化学的ドナーを含有する組成物ならびにその使用 Download PDFInfo
- Publication number
- JP2004520264A JP2004520264A JP2002515293A JP2002515293A JP2004520264A JP 2004520264 A JP2004520264 A JP 2004520264A JP 2002515293 A JP2002515293 A JP 2002515293A JP 2002515293 A JP2002515293 A JP 2002515293A JP 2004520264 A JP2004520264 A JP 2004520264A
- Authority
- JP
- Japan
- Prior art keywords
- iron
- pharmaceutical composition
- nitric oxide
- food supplement
- supplement according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 104
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 35
- 230000004060 metabolic process Effects 0.000 title claims abstract description 26
- 239000002243 precursor Substances 0.000 title claims abstract description 26
- 239000000126 substance Substances 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 41
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical class [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims abstract description 10
- 208000007502 anemia Diseases 0.000 claims abstract description 8
- 206010003549 asthenia Diseases 0.000 claims abstract description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 135
- 229910052742 iron Inorganic materials 0.000 claims description 66
- 235000018102 proteins Nutrition 0.000 claims description 33
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 18
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 18
- 229930064664 L-arginine Natural products 0.000 claims description 16
- 235000014852 L-arginine Nutrition 0.000 claims description 16
- 102000010445 Lactoferrin Human genes 0.000 claims description 16
- 108010063045 Lactoferrin Proteins 0.000 claims description 16
- 150000002505 iron Chemical class 0.000 claims description 16
- 235000021242 lactoferrin Nutrition 0.000 claims description 16
- 229940078795 lactoferrin Drugs 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical group CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004338 Transferrin Human genes 0.000 claims description 3
- 108090000901 Transferrin Proteins 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 claims description 2
- IMWCPTKSESEZCL-SPSNFJOYSA-H (e)-but-2-enedioate;iron(3+) Chemical compound [Fe+3].[Fe+3].[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O IMWCPTKSESEZCL-SPSNFJOYSA-H 0.000 claims description 2
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical group Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 2
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
- 241000219745 Lupinus Species 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 claims description 2
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 claims description 2
- VEPSWGHMGZQCIN-UHFFFAOYSA-H ferric oxalate Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O VEPSWGHMGZQCIN-UHFFFAOYSA-H 0.000 claims description 2
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims description 2
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 2
- 150000008535 L-arginines Chemical class 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000008139 complexing agent Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 206010022971 Iron Deficiencies Diseases 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010061958 Food Intolerance Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 159000000014 iron salts Chemical class 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0009883A FR2812200B1 (fr) | 2000-07-27 | 2000-07-27 | Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote ; et utilisations |
| PCT/FR2001/002469 WO2002009740A1 (fr) | 2000-07-27 | 2001-07-27 | Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote et utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004520264A true JP2004520264A (ja) | 2004-07-08 |
| JP2004520264A5 JP2004520264A5 (https=) | 2005-03-03 |
Family
ID=8852998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002515293A Pending JP2004520264A (ja) | 2000-07-27 | 2001-07-27 | 鉄錯化蛋白質および一酸化窒素代謝の前駆体および／または一酸化窒素の化学的ドナーを含有する組成物ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6984624B2 (https=) |
| EP (1) | EP1303296B1 (https=) |
| JP (1) | JP2004520264A (https=) |
| AT (1) | ATE292978T1 (https=) |
| AU (1) | AU2001279922A1 (https=) |
| DE (1) | DE60110084D1 (https=) |
| FR (1) | FR2812200B1 (https=) |
| WO (1) | WO2002009740A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009101789A1 (ja) * | 2008-02-14 | 2009-08-20 | Morinaga Milk Industry Co., Ltd. | 卵巣機能改善剤 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10215315A1 (de) * | 2002-04-05 | 2003-11-20 | Aventis Behring Gmbh Intellect | Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels |
| EP1675501B1 (en) | 2003-09-12 | 2013-09-04 | Or-Nim Medical Ltd. | Noninvasive optical monitoring of region of interest |
| EP1589283B1 (en) * | 2004-04-23 | 2006-08-16 | Abb Research Ltd. | Model and control of a waste combustion process |
| ZA200702421B (en) * | 2004-10-08 | 2008-09-25 | Unilever Plc | Iron complex for use in the treatment and/or prevention of nutritional disorders |
| EP1867330A4 (en) * | 2005-03-30 | 2012-01-25 | Kyowa Hakko Bio Co Ltd | METHOD FOR IMPROVING THE STORAGE STABILITY OF A SUBSTANCE |
| US20090202613A1 (en) * | 2008-02-11 | 2009-08-13 | Tabatchnick Fine Foods, Inc. | Nutritionally Enhanced Therapeutic Preventative Food Supplement and Method of Making Same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE192922T1 (de) * | 1993-11-02 | 2000-06-15 | Us Health | Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden |
| US5827729A (en) * | 1996-04-23 | 1998-10-27 | Advanced Tissue Sciences | Diffusion gradient bioreactor and extracorporeal liver device using a three-dimensional liver tissue |
| US6333311B1 (en) * | 1997-02-03 | 2001-12-25 | Pharming | Useful properties of human lactoferrin and variants thereof |
-
2000
- 2000-07-27 FR FR0009883A patent/FR2812200B1/fr not_active Expired - Fee Related
-
2001
- 2001-07-27 AT AT01958190T patent/ATE292978T1/de not_active IP Right Cessation
- 2001-07-27 DE DE60110084T patent/DE60110084D1/de not_active Expired - Lifetime
- 2001-07-27 WO PCT/FR2001/002469 patent/WO2002009740A1/fr not_active Ceased
- 2001-07-27 JP JP2002515293A patent/JP2004520264A/ja active Pending
- 2001-07-27 US US10/333,554 patent/US6984624B2/en not_active Expired - Fee Related
- 2001-07-27 EP EP01958190A patent/EP1303296B1/fr not_active Expired - Lifetime
- 2001-07-27 AU AU2001279922A patent/AU2001279922A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009101789A1 (ja) * | 2008-02-14 | 2009-08-20 | Morinaga Milk Industry Co., Ltd. | 卵巣機能改善剤 |
| JP5022454B2 (ja) * | 2008-02-14 | 2012-09-12 | 森永乳業株式会社 | 卵巣機能改善剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE292978T1 (de) | 2005-04-15 |
| EP1303296A1 (fr) | 2003-04-23 |
| DE60110084D1 (de) | 2005-05-19 |
| US6984624B2 (en) | 2006-01-10 |
| EP1303296B1 (fr) | 2005-04-13 |
| US20040033945A1 (en) | 2004-02-19 |
| WO2002009740A1 (fr) | 2002-02-07 |
| FR2812200B1 (fr) | 2003-01-03 |
| FR2812200A1 (fr) | 2002-02-01 |
| AU2001279922A1 (en) | 2002-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8968726B2 (en) | Lactoferrin and angiogenin compositions and uses thereof | |
| Ianiro et al. | Lactoferrin: From the structure to the functional orchestration of iron homeostasis | |
| Tarnopolsky et al. | Acute and moderate-term creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans | |
| CN101212961A (zh) | 羟甲基丁酸盐组合物及其应用 | |
| JP4327607B2 (ja) | ラクトフェリン | |
| Mok et al. | Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy | |
| IL182950A (en) | Liposomal suspension for oral glutathione administration | |
| JP2021529736A (ja) | 炎症の軽減又は治療のための組成物及び方法 | |
| ES2256070T3 (es) | Actividad antimicrobiana de la primera agrupacion cationica de lactoferrina humana. | |
| AU2015373326B2 (en) | Use of probiotics to increase male fertility | |
| WO2011150395A2 (en) | Nutrient compositions | |
| JP2004520264A (ja) | 鉄錯化蛋白質および一酸化窒素代謝の前駆体および／または一酸化窒素の化学的ドナーを含有する組成物ならびにその使用 | |
| JP2005525329A (ja) | 向精神薬とセレンから成る配合物 | |
| AU2004241884A2 (en) | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | |
| WO2006105155A2 (en) | Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms | |
| Ono et al. | Hypervitaminosis A: a contributing factor to anemia in regular dialysis patients | |
| RU2760674C1 (ru) | Применение препаратов растения polyscias filicifolia или его фрагментов для лечения элементозов и их последствий | |
| EP2234611B1 (en) | Composition for treating sterile inflammation | |
| US20150174218A1 (en) | ANGIOGENIN COMPLEXES (ANGex) WITH ANABOLIC HORMONES FOR IMPROVING BONE HEALTH | |
| RU2372899C2 (ru) | Фармацевтическая композиция для лечения псориаза, содержащая l-серин, l-изолейцин, фолиевую кислоту и микроэлементы | |
| Elgar | N-acetylcysteine: A Review of Clinical Use and Efficacy | |
| US7060677B1 (en) | Antimicrobial activity of the first cationic cluster of human lactoferrin | |
| GB2323030A (en) | Dietary supplements for immunocompromised patients | |
| WO2012038590A1 (en) | Improved dietary substitution for treating or preventing cancer | |
| WO2010017403A9 (en) | Therapeutic compositions, devices and methods for observing treated tissues |